Get started
PTC Therapeutics, Inc.PTC Therapeutics, Inc.PTC Therapeutics, Inc.

PTC Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

PTCT chart


Full chart

PTCT upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.50 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−5.94 USD
Net income (FY)
‪−626.60 M‬ USD
Revenue (FY)
‪937.82 M‬ USD
Shares float
‪74.46 M‬
Beta (1Y)
1.95

Employees


Employees (FY)
995
Change (1Y)
−415 −29.43%
Revenue / Employee (1Y)
‪942.53 K‬ USD
Net income / Employee (1Y)
‪−629.75 K‬ USD

About PTC Therapeutics, Inc.


Sector
Health Technology
CEO
Matthew B. Klein
Headquarters
Warren
Website
ptcbio.com
Founded
1998
FIGI
BBG000QT15P7
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

PTCT news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

PTCT highest yielding bonds


PTCT5396017
PTC Therapeutics, Inc. 1.5% 15-SEP-2026
Yield to maturity
−7.37%
Maturity date
Sep 15, 2026

Explore more bonds 

Frequently Asked Questions


The current price of PTCT is 45.35 USD — it has decreased by −0.46% in the past 24 hours. Watch PTC Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange PTC Therapeutics, Inc. stocks are traded under the ticker PTCT.
PTCT stock has fallen by −5.07% compared to the previous week, the month change is a 5.39% rise, over the last year PTC Therapeutics, Inc. has showed a 58.34% increase.
We've gathered analysts' opinions on PTC Therapeutics, Inc. future price: according to them, PTCT price has a max estimate of 80.00 USD and a min estimate of 32.00 USD. Watch PTCT chart and read a more detailed PTC Therapeutics, Inc. stock forecast: see what analysts think of PTC Therapeutics, Inc. and suggest that you do with its stocks.
PTCT reached its all-time high on Apr 9, 2015 with the price of 78.72 USD, and its all-time low was 4.03 USD and was reached on Nov 3, 2016. View more price dynamics on PTCT chart.
See other stocks reaching their highest and lowest prices.
PTCT stock is 2.67% volatile and has beta coefficient of 1.95. Track PTC Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is PTC Therapeutics, Inc. there?
Today PTC Therapeutics, Inc. has the market capitalization of ‪3.50 B‬, it has decreased by −3.11% over the last week.
Yes, you can track PTC Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
PTC Therapeutics, Inc. is going to release the next earnings report on Feb 25, 2025. Keep track of upcoming events with our Earnings Calendar.
PTCT earnings for the last quarter are −1.39 USD per share, whereas the estimation was −1.52 USD resulting in a 8.61% surprise. The estimated earnings for the next quarter are −0.76 USD per share. See more details about PTC Therapeutics, Inc. earnings.
PTC Therapeutics, Inc. revenue for the last quarter amounts to ‪196.79 M‬ USD, despite the estimated figure of ‪170.59 M‬ USD. In the next quarter, revenue is expected to reach ‪213.71 M‬ USD.
PTCT net income for the last quarter is ‪−106.65 M‬ USD, while the quarter before that showed ‪−99.18 M‬ USD of net income which accounts for −7.54% change. Track more PTC Therapeutics, Inc. financial stats to get the full picture.
No, PTCT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 995.00 employees. See our rating of the largest employees — is PTC Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PTC Therapeutics, Inc. EBITDA is ‪21.85 M‬ USD, and current EBITDA margin is −12.03%. See more stats in PTC Therapeutics, Inc. financial statements.
Like other stocks, PTCT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PTC Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PTC Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PTC Therapeutics, Inc. stock shows the strong buy signal. See more of PTC Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.